Terminated PHASE3 INTERVENTIONAL 2-arm NCT05605093

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions COVID-19

Interventions Shionogi Protease Inhibitor (S-217622) placebo

Updated 29 times since 2022 Last updated: Nov 13, 2025 Started: Dec 23, 2022 Primary completion: Oct 28, 2025 Completion: Oct 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

DSMB closed due to futility.

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

A PHASE3 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 29 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

29 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3

▶ Show 24 earlier versions

May 2025 — Jul 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Dec 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Abilene, United States , Abuja, Nigeria , Albuquerque, United States , Alexandroupoli, Greece , Ann Arbor, United States , Athens, Greece , Aurora, United States , Badalona, Spain and 134 more locations